ProCE Banner Activity

CME

Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies: Independent 2023 Conference/Congress Coverage

Text Module

Text module with experts’ insights on key studies presented at key global conferences on gynecologic cancers including topics of incorporating immunotherapies into the standard of care in gynecologic cancers, novel targeted agents, and combinations in development, and updated long-term data and confirmatory trial results.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: December 13, 2023

Expiration: December 12, 2024

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Linda R. Duska

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Keiichi Fujiwara

Keiichi Fujiwara, MD, PhD

Professor of Gynecologic Oncology
Saiama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan

Alexandra Leary

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

David Scott Miller

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

Kathleen Moore

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma

Ana Oaknin

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Brian Slomovitz

Brian Slomovitz, MD, MS, FACOG

Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor 
Obsterics and Gynecology 
Florida International University
Member, Board of Directors 
GOG Foundation
Uterine Cancer Lead 
GOG Partners
Miami, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Target Audience

This educational program is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals who treat patients with gynecologic cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners in selecting individualized treatment regimens for patients with gynecologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new data in cervical, endometrial, and ovarian cancers to clinical practice to expand treatment options and improve outcomes for patients with gynecologic malignancies

  • Plan individualized treatment strategies, incorporating novel therapies and combination strategies as appropriate, for patients with cervical, endometrial, and ovarian cancers

  • Assess predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility

  • Provide education and support throughout all stages of diagnosis and treatment to populations of patients with gynecologic cancers who are at increased risk for poor prognosis

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Nicoletta Colombo, MD: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Immunogen Merck Sharp & Doheme, Mersana, Nuvation, Oncxerna, Pfizer, Pieris, Roche.

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Linda R. Duska, MD, MPH, FACOG, FACS, FASCO: researcher (paid to institution): Aduro Biotech Inc, ARCH Oncology, CE3 Inc, Clinipace Inc, Corcept Therapeutics, Eisia, GlaxoSmithKline, Harpoon Therapeutics, K-Group Beta, Leap Therapeutics, Lycera, Ludwig Institute for Cancer Research, Merck Sharp and Dohme, NRG, OncoQuest, Pfizer, PharmaMar, Plexxikon, Psi Pharma Support America, Seattle Genetics, Syndax; data safety monitoring committee: Agenus, Inovio.

Keiichi Fujiwara, MD, PhD

Professor of Gynecologic Oncology
Saiama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan

Keiichi Fujiwara, MD, PhD: consultant/advisor/speaker: Genmab, Sanofi, Seagen, Takeda.

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Alexandra Leary, MD, PhD: consultant/advisor/speaker: Ability Pharma, Apmonia, AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Owkin; researcher: Ability Pharma, Apmonia, AstraZeneca, Genmab, GlaxoSmithKline, Incyte, Merck Sharp & Dohme, Oseimmuno, Owkin, Pfizer.

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp and Dohme.

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

David Scott Miller, MD, FACOG, FACS: consultant/advisor/speaker: AbbVie, Agenus, AstraZeneca, Asymmetric, Boston Biomedical Research Institute, Eisai, Eisai Europe Limited, EMD Serono, GlaxoSmithKline, Immunogen, Incyte, iTeos Belgium SA, Karyopharm, Merck Sharp & Dohme, Myriad, Novartis, Novocure, Seagen, Tarveda Therapeutics; researcher (paid to institution): Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akesobio, Aprea AB, AstraZeneca, Immunogen, Incyte, Janssen, Karyopharm, Mateon, Merck Sharp & Dohme, Millenium, NVision, Novartis, Pfizer, Regeneron, Syros, Tesaro, Tracon, US Biotest, Xenetic; researcher: EMD Serono Research & Development, Leap.

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma

Kathleen Moore, MD, MS: consultant/advisor/speaker: Aadi, AstraZeneca, Aravive, Alkermes, Blueprint Pharma, Caris, Clovis, Eisai, Genentech, GlaxoSmithKline, Immunogen, Inxmed, Imab, Janssen, Lilly, Merck, Mereo, Mersana, Myriad, Novartis, Onconova, Oncxerna, Pannavance, Regeneron, VBL Therapeutics, Verastem, Zentalis; independent contractor: GOG Partners Associate Director.

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Ana Oaknin, MD, PhD: consultant/advisor/speaker: Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelisis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, ImmunoGen, Itheos, Merck Sharp & Dohme de España, Mersana Therapeutics, NovoCure, OneXerna Therapeutics, PharmaMar, Regeneron, SA Pharma, Sattucklabs, Seagen and Sutro Biopharma.

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Isabelle Ray-Coquard, MD, PhD: consultant/advisor/speaker: Adaptimmune, Agenus, Amgen, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Deciphera, Eisai, Exelixis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, ImmunoGen, Merck Sharp & Dohme, Mersana Therapeutics, NovoCure, OncXerna Therapeutics, PharmaMar, Regeneron, SA Pharma, Seagen, Sutro Biopharma.

Brian Slomovitz, MD, MS, FACOG

Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor 
Obsterics and Gynecology 
Florida International University
Member, Board of Directors 
GOG Foundation
Uterine Cancer Lead 
GOG Partners
Miami, Florida

Brian Slomovitz, MD, MS FACOG: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, Genmab, Gilead, GlaxoSmithKline, Merck, Novartis, Novocure, Regeneron, Seagen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 13, 2023, through December 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.